Company / SG&A Expense
BioLife Solutions, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$45.5M
FY2025
5-year range
$33.3M / $45.5M
FY2021-FY2025
Trend
+12.0%
vs FY2024
Sector context
#140 of 152
Health Care
What the data says
Among 152 Health Care companies, BioLife Solutions, Inc. is in the top 8% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $3M in FY2018 to $46M in FY2025.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of +24.4%.
Increased from $43M to $46M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +11.0%
- 5-Year CAGR
- +24.4%
- 10-Year CAGR
- -
Sector benchmark
Top 8% in Health CareTop 8% of 152This company $45.5M Sector average $182.7B
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +24.4%, indicating consistent growth.
- In FY2025, sg&a expense increased 12.0% year-over-year.
- Ranks #140 out of 152 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 4.67 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.5M | +12.0% |
| FY2024 | $40.6M | -5.1% |
| FY2023 | $42.8M | +28.7% |
| FY2022 | $33.3M | -1.2% |
| FY2021 | $33.7M | +120.4% |
| FY2020 | $15.3M | +71.7% |
| FY2019 | $8.9M | +224.1% |
| FY2018 | $2.7M | -39.3% |
| FY2017 | $4.5M | -1.5% |
| FY2016 | $4.6M | -5.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026